U.S., Feb. 7 -- ClinicalTrials.gov registry received information related to the study (NCT06813170) titled 'Diet With or Without Metarecod(R) in Obese Subjects With Type 2 Diabetes' on Jan. 15.
Brief Summary: Obesity is considered the largest chronic non-communicable disease (globesity) worldwide with a growing trend in the near future. Weight loss programs are strongly recommended in obese patients, especially with type 1 diabetes mellitus (T2DM), although the majority of subjects do not reach or maintain the recommended weight loss target with nutritional intervention alone and one-third of those who achieve a significant weight loss returns to original body weight within one year. Metarecod(R) (Neopolicaptil Gel Retard) is a substance b...